<DOC>
	<DOCNO>NCT03032965</DOCNO>
	<brief_summary>The purpose study determine additional ablation first procedure result ability medically induce quiet atrial arrhythmia improve clinical outcome patient atrial fibrillation thus decrease need additional ablation procedure .</brief_summary>
	<brief_title>Adenosine Assess Complete Conduction Block During Catheter Ablation Paroxysmal Atrial Fibrillation</brief_title>
	<detailed_description>Hypothesis : 1 . Adenosine reveals incomplete conduction block due partial tissue injury/stunning catheter ablation atrial fibrillation . 2 . Identification incomplete conduction block adenosine improve clinical outcome include increase efficacy decrease need repeat procedure catheter ablation atrial fibrillation . Objectives : 1 . In patient paroxysmal Atrial Fibrillation ( AF ) , prevalence Pulmonary Vein ( PV ) reconnection adenosine infusion complete PV isolation use conventional technique determine . 2 . Patients randomized ablation achieve complete isolation adenosine infusion v ablation . 3 . Primary endpoint study freedom atrial arrhythmias 6 month single ablation procedure absence antiarrhythmic drug therapy . 4 . Secondary endpoint include number repeat ablation procedure document recurrence symptomatic AF atrial flutter/tachycardia , outcome 2 ablation procedure ; Proportion patient AF atrial flutter/tachycardia occur first three month post ablation , prevalence recovery conduction PVs repeat ablation procedure group , procedure duration , incidence peri-procedural complication include stroke , PV stenosis , cardiac perforation , atrio-esophageal fistula , death .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Adenosine</mesh_term>
	<mesh_term>Isoproterenol</mesh_term>
	<criteria>1 . Patients &gt; 18 &lt; 75 able give inform consent undergo atrial fibrillation ablation procedure . 2 . Paroxysmal Atrial fibrillation last = 7 day selfterminating . It consider recurrent two episode occur . 3 . Failure unwilling take class I III antiarrhythmic drug 1 . History asthma 2 . Patients severe coronary artery disease , stable/unstable angina , ongoing myocardial ischemia 3 . Previous cardiac surgery ( exclude CABG mitral valve surgery ) 4 . Symptomatic congestive heart failure include limited NYHA III/IV and/or document ejection fraction &lt; 40 % measure acceptable cardiac testing , 5 . Left atrial diameter &gt; 55mm 6 . Moderate severe mitral aortic valve disease 7 . Myocardial infarction within three month enrollment 8 . Congenital heart disease increase risk ablative procedure 9 . Prior ASD/PFO closure device use percutaneous approach 10 . Hypertrophic cardiomyopathy ( LV wall thickness &gt; 1.5mm ) 11 . Pulmonary Hypertension ( mean systolic PA pressure &gt; 50mmHg Doppler echocardiography 12 . Any prior ablation atrial fibrillation 13 . Enrollment arrhythmia protocol 14 . Any ventricular arrhythmia treat arrhythmia management may interfere study 15 . Active infection sepsis 16 . Any history cerebrovascular disease include stroke TIAs 17 . Pregnancy lactation 18 . Left atrial thrombus time ablation 19 . Untreatable allergy contrast medium 20 . Any diagnosis atrial fibrillation secondary electrolyte disturbance , thyroid disease , reversible noncardiovascular cause 21 . History blood clotting ( bleed thrombotic ) abnormalities 22 . Known sensitivity heparin warfarin 23 . Severe COPD ( define FEV1 &lt; 1 ) 24 . Severe comorbidity poor general physical/mental health , opinion investigator , allow patient good study candidate ( i.e . disease process , mental capacity , substance abuse , shorten life expectancy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>atrial fibrillation</keyword>
	<keyword>ablation</keyword>
	<keyword>adenosine</keyword>
</DOC>